US 11,291,687 · Application 17/480,534 · Granted Apr 5, 2022
US 11,291,687
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
Estimated expiration
January 5, 2038
11y 122d remaining
Earliest effective filing
Jan 5, 2018
+ 20 years
Jan 5, 2038
PTA +0d
Jan 5, 2038
TD cap (US 10,420,799)
Jan 5, 2038
Final
Jan 5, 2038
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- September 21, 2021
- Earliest effective filing
- January 5, 2018
- Issue date
- April 5, 2022
- PTA
- 0 days
- Base expiry (before PTA)
- January 5, 2038
January 5, 2018 + 20 years = January 5, 2038
- Continuation of application 17/383,280, filed Jul 22, 2021, issued as US 11,304,979
- Continuation of application 17/326,088, filed May 20, 2021, issued as US 11,202,803
- Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
- Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
- Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
- Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
- Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
- Continuation of application 17/326,088, filed May 20, 2021, issued as US 11,202,803
- Continuation of application 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
- Divisional of application 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
- PRO62/478,506 — Provisional — not used for base term
- PRO62/539,410 — Provisional — not used for base term
- PRO62/548,306 — Provisional — not used for base term
- PRO62/554,538 — Provisional — not used for base term
- PRO62/559,374 — Provisional — not used for base term
- PRO62/567,121 — Provisional — not used for base term
- PRO62/577,655 — Provisional — not used for base term
- PRO62/582,874 — Provisional — not used for base term
- PRO62/596,374 — Provisional — not used for base term
- PRO62/478,506 — Provisional — not used for base term
- PRO62/539,410 — Provisional — not used for base term
- PRO62/548,306 — Provisional — not used for base term
- PRO62/554,538 — Provisional — not used for base term
- PRO62/559,374 — Provisional — not used for base term
- PRO62/567,121 — Provisional — not used for base term
- PRO62/577,655 — Provisional — not used for base term
- PRO62/582,874 — Provisional — not used for base term
- PRO62/596,374 — Provisional — not used for base term
- PRO62/478,506 — Provisional — not used for base term
- PRO62/539,410 — Provisional — not used for base term
- PRO62/548,306 — Provisional — not used for base term
- PRO62/554,538 — Provisional — not used for base term
- PRO62/559,374 — Provisional — not used for base term
- PRO62/567,121 — Provisional — not used for base term
- PRO62/577,655 — Provisional — not used for base term
- PRO62/582,874 — Provisional — not used for base term
- PRO62/596,374 — Provisional — not used for base term
- PRO62/478,506 — Provisional — not used for base term
- PRO62/539,410 — Provisional — not used for base term
- PRO62/548,306 — Provisional — not used for base term
- PRO62/554,538 — Provisional — not used for base term
- PRO62/559,374 — Provisional — not used for base term
- PRO62/567,121 — Provisional — not used for base term
- PRO62/577,655 — Provisional — not used for base term
- PRO62/582,874 — Provisional — not used for base term
- PRO62/596,374 — Provisional — not used for base term
- PRO62/478,506 — Provisional — not used for base term
- PRO62/539,410 — Provisional — not used for base term
- PRO62/548,306 — Provisional — not used for base term
- PRO62/554,538 — Provisional — not used for base term
- PRO62/559,374 — Provisional — not used for base term
- PRO62/567,121 — Provisional — not used for base term
- PRO62/577,655 — Provisional — not used for base term
- PRO62/582,874 — Provisional — not used for base term
- PRO62/596,374 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to January 5, 2038 (earliest expiring referenced patent: US 10,420,799)
US 10,420,799· Application 16/136,157Capping patent
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
- Filing date
- Sep 19, 2018
- Earliest effective filing
- Jan 5, 2018
- Issue date
- Sep 24, 2019
- PTA
- 0 days
- Calculated expiration
- Jan 5, 2038
Continuation of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257
Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Jan 5, 2018 + 20y = Jan 5, 2038
US 11,291,687· Application 17/480,534(from application 17/480,534)
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
- Filing date
- Sep 21, 2021
- Earliest effective filing
- Jan 5, 2018
- Issue date
- Apr 5, 2022
- PTA
- 0 days
- Calculated expiration
- Jan 5, 2038
Continuation of 17/383,280, filed Jul 22, 2021, issued as US 11,304,979
Continuation of 17/326,088, filed May 20, 2021, issued as US 11,202,803
Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Continuation of 17/326,088, filed May 20, 2021, issued as US 11,202,803
Continuation of 17/147,073, filed Jan 12, 2021, issued as US 11,013,770
Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Jan 5, 2018 + 20y = Jan 5, 2038
US 10,653,723· Application 16/746,416
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
- Filing date
- Jan 17, 2020
- Earliest effective filing
- Jan 5, 2018
- Issue date
- May 19, 2020
- PTA
- 0 days
- Calculated expiration
- Jan 5, 2038
Continuation of 16/192,707, filed Nov 15, 2018, issued as US 10,537,595
Divisional of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257
Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Continuation of 15/874,718, filed Jan 18, 2018, issued as US 10,166,257
Continuation of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Jan 5, 2018 + 20y = Jan 5, 2038
US 11,007,226· Application 17/127,790
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
- Filing date
- Dec 18, 2020
- Earliest effective filing
- Jan 5, 2018
- Issue date
- May 18, 2021
- PTA
- 0 days
- Calculated expiration
- Jan 5, 2038
Divisional of 15/863,634, filed Jan 5, 2018, issued as US 10,894,063
Jan 5, 2018 + 20y = Jan 5, 2038
Notes (1)
- [TD_DOCS_TRUNCATED] Found 9 filed TD documents; parsing first 3 only
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/480,534 · US 11,291,687
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 11,291,687: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11291687Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.